Jay Roodselaar1, Yifan Zhou2, David Leppert2, Anja E Hauser2, Eduard Urich2, Daniel C Anthony2. 1. From the Department of Pharmacology (J.R., Y.Z.), University of Oxford; University of Basel (D.L.), Switzerland; Deutsches Rheumaforschungszentrum (DRFZ) and Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin (J.R., A.E.H.), Germany; Roche Innovation Center (E.U.), Basel, Switzerland; and Department of Pharmacology (D.C.A.), University of Oxford, UK. jay.roodselaar@pharm.ox.ac.uk. 2. From the Department of Pharmacology (J.R., Y.Z.), University of Oxford; University of Basel (D.L.), Switzerland; Deutsches Rheumaforschungszentrum (DRFZ) and Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin (J.R., A.E.H.), Germany; Roche Innovation Center (E.U.), Basel, Switzerland; and Department of Pharmacology (D.C.A.), University of Oxford, UK.
Abstract
OBJECTIVE: Therapies targeting B cells have been used in the clinic for multiple sclerosis (MS). In patients with relapsing MS, anti-CD20 therapy often suppresses relapse activity; yet, their effect on disease progression has been disappointing. Most anti-CD20 therapeutic antibodies are type I, but within the unique microenvironment of the brain, type II antibodies may be more beneficial, as type II antibodies exhibit reduced complement-dependent cytotoxicity and they have an increased capacity to induce direct cell death that is independent of the host immune response. METHODS: We compared the effect of type I with type II anti-CD20 therapy in a new rodent model of secondary progressive MS (SPMS), which recapitulates the principal histopathologic features of MS including meningeal B-cell aggregates. Focal MS-like lesions were induced by injecting heat-killed Mycobacterium tuberculosis into the piriform cortex of MOG-immunized mice. Groups of mice were treated with anti-CD20 antibodies (type I [rituxumab, 10 mg/kg] or type II [GA101, 10 mg/kg]) 4 weeks after lesion initiation, and outcomes were evaluated by immunohistochemistry. RESULTS: Anti-CD20 therapy decreased the extent of glial activation, significantly decreased the number of B and T lymphocytes in the lesion, and resulted in disruption of the meningeal aggregates. Moreover, at the given dose, the type II anti-CD20 therapy was more efficacious than the type I and also protected against neuronal death. CONCLUSIONS: These results indicate that anti-CD20 may be an effective therapy for SPMS with B-cell aggregates and that the elimination of CD20+ B cells alone is sufficient to cause disruption of aggregates in the brain.
OBJECTIVE: Therapies targeting B cells have been used in the clinic for multiple sclerosis (MS). In patients with relapsing MS, anti-CD20 therapy often suppresses relapse activity; yet, their effect on disease progression has been disappointing. Most anti-CD20 therapeutic antibodies are type I, but within the unique microenvironment of the brain, type II antibodies may be more beneficial, as type II antibodies exhibit reduced complement-dependent cytotoxicity and they have an increased capacity to induce direct cell death that is independent of the host immune response. METHODS: We compared the effect of type I with type II anti-CD20 therapy in a new rodent model of secondary progressive MS (SPMS), which recapitulates the principal histopathologic features of MS including meningeal B-cell aggregates. Focal MS-like lesions were induced by injecting heat-killed Mycobacterium tuberculosis into the piriform cortex of MOG-immunized mice. Groups of mice were treated with anti-CD20 antibodies (type I [rituxumab, 10 mg/kg] or type II [GA101, 10 mg/kg]) 4 weeks after lesion initiation, and outcomes were evaluated by immunohistochemistry. RESULTS: Anti-CD20 therapy decreased the extent of glial activation, significantly decreased the number of B and T lymphocytes in the lesion, and resulted in disruption of the meningeal aggregates. Moreover, at the given dose, the type II anti-CD20 therapy was more efficacious than the type I and also protected against neuronal death. CONCLUSIONS: These results indicate that anti-CD20 may be an effective therapy for SPMS with B-cell aggregates and that the elimination of CD20+ B cells alone is sufficient to cause disruption of aggregates in the brain.
Authors: Roberta Magliozzi; Owain W Howell; Cheryl Reeves; Federico Roncaroli; Richard Nicholas; Barbara Serafini; Francesca Aloisi; Richard Reynolds Journal: Ann Neurol Date: 2010-10 Impact factor: 10.422
Authors: Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith Journal: N Engl J Med Date: 2008-02-14 Impact factor: 91.245
Authors: Anupama Ahuja; Jonathan Shupe; Robert Dunn; Michael Kashgarian; Marilyn R Kehry; Mark J Shlomchik Journal: J Immunol Date: 2007-09-01 Impact factor: 5.422
Authors: Roberta Magliozzi; Owain Howell; Abhilash Vora; Barbara Serafini; Richard Nicholas; Maria Puopolo; Richard Reynolds; Francesca Aloisi Journal: Brain Date: 2007-04 Impact factor: 13.501
Authors: Marie Therese Fischer; Isabella Wimmer; Romana Höftberger; Susanna Gerlach; Lukas Haider; Tobias Zrzavy; Simon Hametner; Don Mahad; Christoph J Binder; Markus Krumbholz; Jan Bauer; Monika Bradl; Hans Lassmann Journal: Brain Date: 2013-05-17 Impact factor: 13.501
Authors: Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann Journal: Brain Date: 2009-03-31 Impact factor: 13.501
Authors: Julia Baguña Torres; Jay Roodselaar; Megan Sealey; Marina Ziehn; Marc Bigaud; Rainer Kneuer; David Leppert; Gisbert Weckbecker; Bart Cornelissen; Daniel C Anthony Journal: Front Immunol Date: 2022-07-28 Impact factor: 8.786